Therma Bright Expands InStatin Investment
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has expanded its investment in InStatin, a company developing an inhaled statin solution for chronic lung conditions like asthma and COPD. This investment is part of a SAFE (Simple Agreement for Future Equity) plan, which will increase Therma's ownership stake from the current 17% at a discount to InStatin's next financing round.
InStatin is initiating preclinical studies to progress towards Phase 1 human trials. The global asthma treatment market is projected to reach USD $30.1 billion by 2030, highlighting significant market potential. Additionally, Therma Bright is in discussions regarding its investment in InVixa, which is developing inhaled statins for COVID-19 pneumonia and ARDS treatment.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha ampliato il suo investimento in InStatin, un'azienda che sviluppa una soluzione di statine inalate per condizioni polmonari croniche come asma e BPCO. Questo investimento fa parte di un piano SAFE (Simple Agreement for Future Equity), che aumenterà la quota di proprietà di Therma dal 17% attuale a un prezzo scontato rispetto al prossimo round di finanziamento di InStatin.
InStatin sta avviando studi preclinici per progredire verso la fase 1 delle sperimentazioni sugli esseri umani. Il mercato globale dei trattamenti per l'asma è previsto raggiungere 30,1 miliardi di dollari USA entro il 2030, evidenziando un significativo potenziale di mercato. Inoltre, Therma Bright è in discussione riguardo al suo investimento in InVixa, che sta sviluppando statine inalate per il trattamento della polmonite da COVID-19 e dell'ARDS.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha ampliado su inversión en InStatin, una empresa que desarrolla una solución de estatinas inhaladas para condiciones pulmonares crónicas como asma y EPOC. Esta inversión es parte de un plan SAFE (Acuerdo Simple para Capital Futuro), que aumentará la participación de propiedad de Therma del 17% actual a un descuento en la próxima ronda de financiamiento de InStatin.
InStatin está iniciando estudios preclínicos para avanzar hacia los ensayos humanos de fase 1. Se proyecta que el mercado global de tratamientos para el asma alcanzará 30,1 mil millones de dólares estadounidenses para 2030, destacando un significativo potencial de mercado. Además, Therma Bright está en discusiones sobre su inversión en InVixa, que está desarrollando estatinas inhaladas para el tratamiento de neumonía por COVID-19 y ARDS.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 InStatin에 대한 투자를 확장했습니다. 이 회사는 천식 및 COPD와 같은 만성 폐 질환을 위한 흡입용 스타틴 솔루션을 개발하고 있습니다. 이 투자는 SAFE(향후 주식에 대한 단순 계약) 계획의 일환으로, InStatin의 다음 자금 조달 라운드에서 할인된 가격으로 Therma의 소유 지분을 현재 17%에서 증가시킬 것입니다.
InStatin은 임상 전 연구를 시작하여 1상 인간 시험을 진행할 준비를 하고 있습니다. 전 세계 천식 치료 시장은 2030년까지 301억 달러에 이를 것으로 예상되며, 이는 상당한 시장 잠재력을 강조합니다. 또한, Therma Bright는 COVID-19 폐렴 및 ARDS 치료를 위한 흡입형 스타틴을 개발 중인 InVixa에 대한 투자에 대해 논의하고 있습니다.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) a élargi son investissement dans InStatin, une entreprise qui développe une solution de statines inhalées pour les affections pulmonaires chroniques telles que l'asthme et la BPCO. Cet investissement s'inscrit dans le cadre d'un plan SAFE (Accord Simple pour Avenir de l'Équité), qui augmentera la part de propriété de Therma de 17% actuellement à un prix réduit par rapport à la prochaine levée de fonds d'InStatin.
InStatin lance des études précliniques pour progresser vers les essais cliniques de phase 1. Le marché mondial des traitements de l'asthme devrait atteindre 30,1 milliards USD d'ici 2030, mettant en évidence un potentiel de marché significatif. De plus, Therma Bright est en discussion concernant son investissement dans InVixa, qui développe des statines inhalées pour le traitement de pneumonie provoquée par COVID-19 et ARDS.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) hat seine Investition in InStatin erweitert, ein Unternehmen, das eine inhalative Statinlösung für chronische Lungenerkrankungen wie Asthma und COPD entwickelt. Diese Investition ist Teil eines SAFE (Simple Agreement for Future Equity)-Plans, der den Eigentumsanteil von Therma von derzeit 17% zu einem Rabatt auf die nächste Finanzierungsrunde von InStatin erhöhen wird.
InStatin initiiert vorklinische Studien, um die Phase 1 der klinischen Prüfungen am Menschen voranzutreiben. Der globale Markt für Asthmabehandlungen wird voraussichtlich bis 2030 30,1 Milliarden USD erreichen, was ein bedeutendes Marktpotential aufzeigt. Darüber hinaus führt Therma Bright Gespräche über ihre Investition in InVixa, das inhalative Statine zur Behandlung von COVID-19-Pneumonie und ARDS entwickelt.
- Expanded investment in InStatin, potentially increasing ownership stake above 17%
- InStatin's inhaled statin solution shows promising lab results for chronic lung conditions
- Global asthma treatment market projected to reach USD $30.1 billion by 2030
- Initiation of preclinical studies for InStatin's solution, progressing towards Phase 1 human trials
- Exact increase in ownership percentage dependent on InStatin's next financing round
- InStatin's solution still in early stages, requiring successful completion of preclinical and clinical trials
Toronto, Ontario--(Newsfile Corp. - August 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its InStatin investment. With the recent capital raise, the Company has advanced funds to expand its investment in InStatin, as part of SAFE investment plan ("SAFE investment") initiated by InStatin.
InStatin is developing a novel solution using inhaled statins for the treatment and management of patients with chronic lung conditions, such as asthma and chronic obstructive pulmonary disease ("COPD"). Prior to Therma's SAFE investment, Therma Bright owned
InStatin's development of its novel statin inhalant solution has shown great results in the lab. InStatin is now initiating the preclinical studies necessary to get to Phase 1 human trials. Both companies are pleased about the prospect of successful trials of this innovative inhalant solution. As noted in earlier press releases, BioSpace news reported that the global asthma treatment market size is anticipated to reach "USD
"We're pleased to expand our investment in InStatin's treatment and management solution for patients suffering from chronic lung conditions and look forward to receiving updates as our partner progresses into its trial phase," shared Rob Fia, CEO of Therma Bright. "The asthma treatment marketplace alone is expected to reach USD
"We're thankful for the investment from Therma Bright, and look forward to using these funds to further our efforts in the development of our InStatin inhalant solution," shared Ijaz Khan, President of InStatin.
In addition to the completion of the investment obligation with InStatin, Therma and InStatin have continued discussions around various options for Therma Bright's investment in InVixa, as announced on September 27, 2023. InVixa is developing inhaled statins to prevent and treat acute lung disease caused by COVID-19. InVixa is fully focused on the development of novel inhaled therapies for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome (ARDS).
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as progressing clinical trials at InStatin, and related information as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218974
FAQ
What is Therma Bright's new investment in InStatin for TBRIF shareholders?
What product is InStatin developing that Therma Bright (TBRIF) is investing in?
What is the market potential for the asthma treatment that Therma Bright (TBRIF) is investing in through InStatin?
What is the current stage of development for InStatin's product that Therma Bright (TBRIF) has invested in?
